Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems
- PMID: 25967538
- DOI: 10.1007/s00228-015-1855-6
Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems
Abstract
Purpose: This study evaluated the effects of cytochrome P450 (CYP) 2D6 polymorphisms on the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects and used paroxetine as a tool drug to compare the performance of traditional phenotype and activity score systems.
Methods: Pharmacokinetic data were evaluated in 24 subjects who received a single oral dose of 25 mg controlled-release paroxetine. Plasma paroxetine concentrations were measured by LC-MS/MS. CYP2D6 genotypes were tested by PCR and direct DNA sequencing. Subjects were classified by two systems of phenotype prediction. In the traditional phenotype system, subjects were classified as extensive metabolizers or intermediate metabolizers; in the activity score system, subjects were divided into four activity groups. Analysis of variance testing was applied to estimate the effects of CYP2D6 polymorphisms on the pharmacokinetics of paroxetine.
Results: With the traditional phenotype system, significant differences were observed in the following pharmacokinetic parameters of paroxetine: t 1/2, C max, AUC0-t, AUC0-inf, Vz/F, and CL/F (all P < 0.05). The AUC or exposure of paroxetine was about 3.5-fold higher in the intermediate metabolizer group than in the extensive metabolizer group. With the activity score system, significant differences were observed in the t 1/2, C max, AUC0-t, AUC0-inf, Vz/F, and CL/F among the four different activity score groups (all P < 0.05). We found that the AUC of paroxetine decreased by around one half as the activity score increased by 0.5.
Conclusion: The pharmacokinetics of controlled-release paroxetine after a single administration was affected by CYP2D6 polymorphisms. Both the traditional phenotype and the activity score systems performed well and distinguished subjects with different drug exposures. The activity score system provided a more detailed classification for the subjects.
Similar articles
-
Polymorphism in CYP2D6 affects the pharmacokinetics and dose escalation of paroxetine controlled-release tablet in healthy Chinese subjects.Int J Clin Pharmacol Ther. 2017 Nov;55(11):853-860. doi: 10.5414/CP203008. Int J Clin Pharmacol Ther. 2017. PMID: 28933337 Clinical Trial.
-
Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.Clin Pharmacol Ther. 2000 May;67(5):567-76. doi: 10.1067/mcp.2000.106128. Clin Pharmacol Ther. 2000. PMID: 10824636
-
Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects .Int J Clin Pharmacol Ther. 2017 Mar;55(3):231-236. doi: 10.5414/CP202636. Int J Clin Pharmacol Ther. 2017. PMID: 27936523 Clinical Trial.
-
CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.Pharmacotherapy. 2020 Jul;40(7):632-647. doi: 10.1002/phar.2434. Epub 2020 Jul 12. Pharmacotherapy. 2020. PMID: 32519344
-
Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.Expert Opin Drug Metab Toxicol. 2015;11(8):1219-32. doi: 10.1517/17425255.2015.1052791. Epub 2015 Jun 1. Expert Opin Drug Metab Toxicol. 2015. PMID: 26028357 Review.
Cited by
-
No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study.Pharmgenomics Pers Med. 2021 Feb 11;14:229-237. doi: 10.2147/PGPM.S281645. eCollection 2021. Pharmgenomics Pers Med. 2021. PMID: 33603442 Free PMC article.
-
The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics.Genes (Basel). 2021 Nov 3;12(11):1758. doi: 10.3390/genes12111758. Genes (Basel). 2021. PMID: 34828364 Free PMC article.
-
Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone.Pharmaceutics. 2022 Aug 18;14(8):1734. doi: 10.3390/pharmaceutics14081734. Pharmaceutics. 2022. PMID: 36015360 Free PMC article.
-
Effect of Cumulative Exposure on the Efficacy of Paroxetine: A Population Pharmacokinetic-Pharmacodynamic and Machine Learning Analyses.CPT Pharmacometrics Syst Pharmacol. 2025 Jun;14(6):1119-1127. doi: 10.1002/psp4.70032. Epub 2025 May 13. CPT Pharmacometrics Syst Pharmacol. 2025. PMID: 40358139 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases